Synergy Pharmaceuticals — Corporate Update (May 2017)
27 slides from Synergy Pharmaceuticals's corporate update, May 3, 2017
Slide 1: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subjec
Slide 2: 2017 Core Business Priorities
2017 CORE BUSINESS PRIORITIES January 19, 2017 FDA approves Trulance for the treatment of adults with CIC March 20, 2017 Synergy begins marketing Trulance in CIC April 12, 2017 Three new patents issued, expected to extend Trulance exclusivity until 2032 OPTIMIZING TRULANCE March 24, 2017 Successfull
Slide 3: Trulance Is Designed to Replicate the Body's Natural GI Peptide - Uroguanylin
TRULANCE IS DESIGNED TO REPLICATE THE BODY’S NATURAL GI PEPTIDE - UROGUANYLIN Naturally occurring GI peptide Regulates bowel function, fluid secretion and stool consistency Activity is pH-sensitive NDDCELCVNVACTGCL UROGUANYLIN Asp3 Asn9 8 Å Single amino acid change provides 8x greater receptor bindi
Slide 4: Trulance: Foundation to Our Success
Positive early launch signals – significant opportunity ahead Expect to launch with IBS-C indication early next year Control 100% worldwide rights Strong patent portfolio with long life span Commercial team and sales force with significant GI experience and several product launches – 100% focused on
Slide 5: Trulance Commercial Update
TRULANCE COMMERCIAL UPDATE Troy Hamilton Chief Commercial Officer May 3, 2017
Slide 6: Trulance Is Well Positioned for Success
TRULANCE IS WELL POSITIONED FOR SUCCESS 7 RIGHT STRATEGY RIGHT TEAM RIGHT MARKET RIGHT PRODUCT
Slide 7: Trulance Is Well Positioned for Success: Right Market
TRULANCE IS WELL POSITIONED FOR SUCCESS 8 RIGHT MARKET RIGHT STRATEGY RIGHT TEAM RIGHT PRODUCT Large, Growing Market Significant Opportunity for Continued Branded Rx Growth Clear Unmet Needs
Slide 8: Estimated Million U.S. Adults Suffer from CIC or IBS-C
ESTIMATED 45 MILLION U.S. ADULTS SUFFER FROM CIC OR IBS-C Estimated U.S. Prevalence (in millions) ~33 million U.S. adults suffer from CIC alone Source: Suares and Ford, Am J Gastroenterol 2011; 106:1582–159; GERD Prevalence : Sharma, Am J Gastroenterol 2008;103(11):2669-2680; Migraine Prevalence : S
Slide 9: New Entrants Are Growing the Market, Not Cannibalizing Existing Products
NEW ENTRANTS ARE GROWING THE MARKET, NOT CANNIBALIZING EXISTING PRODUCTS ~ 4 MM Last four years, TRx volume has grown by nearly 4 million or 30% All Other Rx = Rx lactulose & Rx polyethylene glycol Source: QuintilesIMS, NPA 10 11,729 12,606 12,878 13,412 1,288 1,345 1,476 1,488 1,422 2,112 2,691 13,
Slide 10: Value of the Prescription Constipation Market Has More Than Doubled
VALUE OF THE PRESCRIPTION CONSTIPATION MARKET HAS MORE THAN DOUBLED OVER THE PAST FOUR YEARS + 148% 1,593 $133 All Other Rx = Rx lactulose & Rx polyethylene glycol Source: QuintilesIMS, NSP 11 $182 $184 $171 $166 $326 $378 $436 $467 $382 $654 $959 $642 $945 $1,260 $0 $500 $1,000 $1,500 2013 2014 201
Slide 11: Still an Untapped US Market Opportunity
STILL AN UNTAPPED US MARKET OPPORTUNITY 12 ~ 45MM U.S. ADULTS WITH CIC / IBS-C > 95% currently not treated with branded Rx therapies GROWTH DRIVERS Increasing awareness of “gut health” Significant investment to build market HCP promotion will continue providing appropriate information to prescribers
Slide 12: Still Clear Unmet Needs in the Market
STILL CLEAR UNMET NEEDS IN THE MARKET KEY INSIGHTS Bowel-Centered life Still seeking solutions Dissatisfied with OTCs Seek normalcy PATIENTS Challenging patients Frustrated Recycling Any BM = Good BM HCPs Source: Company Data 13
Slide 13: Trulance Is Well Positioned for Success: Right Product
TRULANCE IS WELL POSITIONED FOR SUCCESS 14 RIGHT PRODUCT Clinical Data Market Research and Customer Insights Label RIGHT STRATEGY RIGHT TEAM RIGHT MARKET
Slide 14: Trulance Provides a New Treatment Option for Millions of Adults with CIC
TRULANCE PROVIDES A NEW TREATMENT OPTION FOR MILLIONS OF ADULTS WITH CIC 15 Pharmacology Only product thought to replicate the pH-sensitive activity of natural uroguanylin Efficacy Evaluated in the two largest Phase 3 CIC trials to-date Safety / Tolerability Diarrhea was most common adverse event (5
Slide 15: Trulance Provides Simple Dosing and Convenient Packaging
TRULANCE PROVIDES SIMPLE DOSING AND CONVENIENT PACKAGING THAT IS PATIENT PREFERRED* Convenient & Innovative Packaging Simple Dosing & Administration Once a day Any time of day With or without food *Source: Company Data 16
Slide 16: Trulance Is Well Positioned for Success: Right Strategy
Launch Brand = Launch Mode Key Launch Strategies and Activities TRULANCE IS WELL POSITIONED FOR SUCCESS RIGHT STRATEGY 17 RIGHT TEAM RIGHT PRODUCT RIGHT MARKET
Slide 17: Less Than 20% of Prescribers Account for 70% of Branded Prescriptions
LESS THAN 20% OF PRESCRIBERS ACCOUNT FOR 70% OF THE TOTAL BRANDED PRESCRIPTIONS 27,713 Docs / 70% of Rx’s ~ 45% are PCP ~ 30% are GEs ~ 18% are NP/PA Decile 3: = 2 Rx’s per month Decile 2: ~ 1 Rx per month Decile 1: = 1 Rx every 3 months Source: QuintilesIMS Xponent - March 2017; excluding non-calle
Slide 18: Less Than 20% of Prescribers Account for 70% of Branded Prescriptions: Key Points
Other Key Points: The ~27K prescribers are within 15K group practices/offices National vs. Subnational Data Reaching these prescribers with an experienced field force and surround sound of promotional efforts LESS THAN 20% OF PRESCRIBERS ACCOUNT FOR 70% OF THE TOTAL BRANDED PRESCRIPTIONS 2.4MM TRx (
Slide 19: Key Launch Strategies
KEY LAUNCH STRATEGIES Key Strategies Drive Awareness of Trulance and Stimulate Trial and Adoption among Targets HCPs PAYERS PATIENTS Ensure Access Activate and Support the Rx Ready Patient 20
Slide 20: Key Launch Strategies and Activities: HCPs
HCPs Drive Awareness of Trulance and Stimulate Trial / Adoption among Targets Ensure Access Activate and Support the Rx Ready Patient Field force of ~ 250 educating > 27,000 Prescribers Over 300,000 sample packs distributed to field to date Initiated speaker bureau program (peer to peer education) L
Slide 21: Key Launch Strategies and Activities: Payers
Removing barriers and gaining commercial open access ~ 60% of patients with commercial insurance have unrestricted access Trulance “Savings-to-Go” program ensures copay of $25/Rx for > 95% of patients with commercial insurance Trulance Support Services Program Medicare Part D and Medicaid Discussion
Slide 22: Key Launch Strategies and Activities: Patients
Trulance Campaign: Point of Care Promotion: ~20,000 offices Web Sponsorships / Display Ads: >16M impressions Search Engine Marketing: > 55,000 clicks Trulance.com visits: ~ 65,000 for consumer site Confront Constipation Campaign: Disease awareness initiative 28 original media placements > 300M media
Slide 23: Trulance Is Well Positioned for Success: Right Team
TRULANCE IS WELL POSITIONED FOR SUCCESS Highly experienced team Significant launch experience Significant GI and PCP experience From peer GI, specialty, and PCP companies RIGHT TEAM 24 RIGHT STRATEGY RIGHT PRODUCT RIGHT MARKET
Slide 24: Synergy Hybrid Sales Model
SYNERGY HYBRID SALES MODEL Hired our own Sales Leaders Synergy Area Business Directors average ~16 years of pharma experience and ~ 10 years in GI Synergy Regional Business Directors average over 11 years of management experience with over 10 years in relevant GI fields Synergy Regional GI Account S
Slide 25: Optimizing the Value of Trulance
Positive early launch signals Early prescriber and patient experience appears promising Executing on our commercial plan Opportunity to “broaden the base” and build off of successful Trulance launch Prepare for IBS-C launch DTC development Evaluate lifecycle opportunities OPTIMIZING THE VALUE OF TRU
Slide 26: Deutsche Bank Healthcare Conference
DEUTSCHE BANK HEALTHCARE CONFERENCE
Slide 27: Synergy Pharmaceuticals
SYNERGY PHARMACEUTICALS
Synergy Pharmaceuticals — Corporate Update (May 2017) on 6ix